Abstract: A method for determining the susceptibility of a bacteria to an antibiotic, comprising transferring one portion of a sample containing living bacterial cells into a bacterial growth medium to create a control sample; transferring another portion of the sample into a bacterial growth medium to which a predetermined amount of antibiotic or predetermined amount of a library of antibiotics has been added to create a test sample; adding an alkyne-modified non-canonical amino acid to both the control sample and test sample during bacterial growth, wherein the alkyne-modified non-canonical amino acid incorporates into surface proteins, internal proteins, or both; reacting the alkyne-containing proteins with an azide-modified detection molecule using click-chemistry to label the cells; detecting the labeled cells using a method that generates a detectable signal; and comparing the signal generated by the control sample to the signal generated by the test sample, wherein a decrease in detectable signal between the con

Abstract: The invention is a general method for improving the performance of the DNA-based vaccines. The method utilizes a complex DNA-generated profile of antigens to extend the effects of DNA-based vaccines and to broaden the immune response. This broadened immune response in turn improves the protection of the recipient from divergent (but related) strains of a pathogen. In addition, it effectively improves the efficacy of DNA-based vaccines used for treatment of viral diseases, including acquired immunity disorder (AIDS). One embodiment, where the target viral pathogen is HIV (the causative agent for aids), the method identifies an orderly set of plasmids of related sequences that may be used to prime a broad and strong immune response to HLA-restricted viral antigens. This mixture of plasmids is thus capable of priming an appropriate immune response to reduce the viral burden in HIV infected patients or to protect uninfected patients from HIV infection.

Abstract: The present invention provides mutated proteins of steroid hormone receptors. These mutated proteins are useful as gene medicines. In particular, these mutated proteins are useful for regulating expression of genes in gene therapy. In addition, the present invention provides plasmids encoding for the desired mutated steroid hormone receptor proteins, as well as cells transfected with those plasmids.